01d7 sample group
CD4/CD8 TIL readouts across LC-1 to LC-4
LC-1 to LC-4 at day 7, compared across IL-2 conditions. Blue: CD8; yellow: CD4. Y-axis: CD3+ TIL counts per 10⁶ total cells.
Study resultsCase study
NSCLC PDO 2.0: immune baseline & IL-2 comparison
CD4/CD8 T-cell counts across IL-2 conditions show immune baseline and condition-related differences in non-small-cell lung cancer (NSCLC) PDO 2.0 samples.
Model & sampleNon-small-cell lung cancer (NSCLC) PDO 2.0 study model
Study setupIL-2 conditions for LC-1 to LC-4 at day 7 and LC-5 at day 28
AssaysCD4 and CD8 counts within CD3-positive TIL populations
STUDY EVIDENCE
NSCLC PDO 2.0: immune baseline and IL-2 condition comparison
Compare CD4/CD8 TIL counts across IL-2 conditions within each sample.
Study design details
01SamplesHuman NSCLC PDOs LC-1 to LC-5
02Reported time pointsLC-1 to LC-4 at d7; LC-5 at d28
03Treatment contextComparison across IL-2 conditions
04Flow readoutCD4 and CD8 signals in CD3+ TILs
Study application
CD4/CD8 TIL counts compare IL-2 conditions within each sample: LC-1 to LC-4 at day 7 and LC-5 at day 28. Longitudinal studies can then follow selected samples over time.
Related models and services
Explore related models and services
PROJECT DISCUSSION
Discuss a study for your program
Tell us which model, assay or finding you want to extend. Our scientists will adapt the approach to your candidate, samples and decision point.